RenBio is excited to provide an update on our ultra long-acting GLP-1 receptor agonist program.

Using our proprietary, DNA-based MYO Technology delivery platform, we are able to achieve >1 year of sustained weight loss in a diet-induced obesity model from a single administration. Please reach out to us to learn more!

We’ll also be at the Biotech Showcase during JPM week in San Francisco this January.